Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Generate Biomedicines
Biotech
Behind Generate's 'feverish' race to raise $400M IPO
Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers.
James Waldron
Feb 27, 2026 3:36am
Generate plans $425M IPO to bankroll phase 3 asthma trials
Feb 23, 2026 9:42am
Flagship-founded antibody biotech Generate is latest to mull IPO
Feb 5, 2026 9:20am
Fierce 15: Where are they now?
Oct 24, 2025 9:00am
Generate gains another $1B-plus Big Pharma partner in Novartis
Sep 24, 2024 6:00am
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
May 3, 2024 8:30am
